nodes	percent_of_prediction	percent_of_DWPC	metapath
Temozolomide—Alkylating Activity—Dacarbazine—pancreatic cancer	0.825	1	CiPCiCtD
Temozolomide—CYP3A4—Tamoxifen—pancreatic cancer	0.0138	0.24	CbGbCtD
Temozolomide—CYP3A4—Erlotinib—pancreatic cancer	0.0117	0.204	CbGbCtD
Temozolomide—CYP3A4—Irinotecan—pancreatic cancer	0.0106	0.185	CbGbCtD
Temozolomide—CYP3A4—Docetaxel—pancreatic cancer	0.00776	0.135	CbGbCtD
Temozolomide—CYP3A4—Sunitinib—pancreatic cancer	0.00772	0.135	CbGbCtD
Temozolomide—CYP3A4—Doxorubicin—pancreatic cancer	0.00578	0.101	CbGbCtD
Temozolomide—Hyperglycaemia—Epirubicin—pancreatic cancer	5.29e-05	0.000451	CcSEcCtD
Temozolomide—Cough—Docetaxel—pancreatic cancer	5.29e-05	0.00045	CcSEcCtD
Temozolomide—Hypersensitivity—Irinotecan—pancreatic cancer	5.27e-05	0.000449	CcSEcCtD
Temozolomide—Pneumonia—Epirubicin—pancreatic cancer	5.26e-05	0.000448	CcSEcCtD
Temozolomide—Convulsion—Docetaxel—pancreatic cancer	5.25e-05	0.000447	CcSEcCtD
Temozolomide—Hypertension—Docetaxel—pancreatic cancer	5.23e-05	0.000446	CcSEcCtD
Temozolomide—Infestation NOS—Epirubicin—pancreatic cancer	5.23e-05	0.000445	CcSEcCtD
Temozolomide—Infestation—Epirubicin—pancreatic cancer	5.23e-05	0.000445	CcSEcCtD
Temozolomide—Bronchitis—Doxorubicin—pancreatic cancer	5.22e-05	0.000445	CcSEcCtD
Temozolomide—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	5.19e-05	0.000442	CcSEcCtD
Temozolomide—Arthralgia—Docetaxel—pancreatic cancer	5.16e-05	0.000439	CcSEcCtD
Temozolomide—Myalgia—Docetaxel—pancreatic cancer	5.16e-05	0.000439	CcSEcCtD
Temozolomide—Nausea—Sunitinib—pancreatic cancer	5.16e-05	0.000439	CcSEcCtD
Temozolomide—Pancytopenia—Doxorubicin—pancreatic cancer	5.16e-05	0.000439	CcSEcCtD
Temozolomide—Asthenia—Irinotecan—pancreatic cancer	5.13e-05	0.000437	CcSEcCtD
Temozolomide—Neuropathy peripheral—Epirubicin—pancreatic cancer	5.13e-05	0.000437	CcSEcCtD
Temozolomide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	5.13e-05	0.000436	CcSEcCtD
Temozolomide—Stomatitis—Epirubicin—pancreatic cancer	5.1e-05	0.000434	CcSEcCtD
Temozolomide—Urinary tract infection—Epirubicin—pancreatic cancer	5.09e-05	0.000433	CcSEcCtD
Temozolomide—Dysuria—Doxorubicin—pancreatic cancer	5.08e-05	0.000432	CcSEcCtD
Temozolomide—Neutropenia—Doxorubicin—pancreatic cancer	5.08e-05	0.000432	CcSEcCtD
Temozolomide—Hypersensitivity—Fluorouracil—pancreatic cancer	5.05e-05	0.00043	CcSEcCtD
Temozolomide—Dry mouth—Docetaxel—pancreatic cancer	5.05e-05	0.00043	CcSEcCtD
Temozolomide—Upper respiratory tract infection—Doxorubicin—pancreatic cancer	5.05e-05	0.00043	CcSEcCtD
Temozolomide—Pollakiuria—Doxorubicin—pancreatic cancer	5.02e-05	0.000427	CcSEcCtD
Temozolomide—Asthenia—Gemcitabine—pancreatic cancer	5e-05	0.000426	CcSEcCtD
Temozolomide—Confusional state—Docetaxel—pancreatic cancer	4.99e-05	0.000425	CcSEcCtD
Temozolomide—Photosensitivity reaction—Doxorubicin—pancreatic cancer	4.96e-05	0.000422	CcSEcCtD
Temozolomide—Hepatobiliary disease—Epirubicin—pancreatic cancer	4.95e-05	0.000421	CcSEcCtD
Temozolomide—Oedema—Docetaxel—pancreatic cancer	4.95e-05	0.000421	CcSEcCtD
Temozolomide—Anaphylactic shock—Docetaxel—pancreatic cancer	4.95e-05	0.000421	CcSEcCtD
Temozolomide—Weight increased—Doxorubicin—pancreatic cancer	4.94e-05	0.000421	CcSEcCtD
Temozolomide—Pruritus—Gemcitabine—pancreatic cancer	4.93e-05	0.00042	CcSEcCtD
Temozolomide—Infection—Docetaxel—pancreatic cancer	4.91e-05	0.000418	CcSEcCtD
Temozolomide—Weight decreased—Doxorubicin—pancreatic cancer	4.91e-05	0.000418	CcSEcCtD
Temozolomide—Sinusitis—Epirubicin—pancreatic cancer	4.91e-05	0.000418	CcSEcCtD
Temozolomide—Hyperglycaemia—Doxorubicin—pancreatic cancer	4.9e-05	0.000417	CcSEcCtD
Temozolomide—Diarrhoea—Irinotecan—pancreatic cancer	4.9e-05	0.000417	CcSEcCtD
Temozolomide—Pneumonia—Doxorubicin—pancreatic cancer	4.87e-05	0.000415	CcSEcCtD
Temozolomide—Nervous system disorder—Docetaxel—pancreatic cancer	4.85e-05	0.000413	CcSEcCtD
Temozolomide—Pruritus—Fluorouracil—pancreatic cancer	4.85e-05	0.000413	CcSEcCtD
Temozolomide—Thrombocytopenia—Docetaxel—pancreatic cancer	4.84e-05	0.000412	CcSEcCtD
Temozolomide—Infestation NOS—Doxorubicin—pancreatic cancer	4.84e-05	0.000412	CcSEcCtD
Temozolomide—Infestation—Doxorubicin—pancreatic cancer	4.84e-05	0.000412	CcSEcCtD
Temozolomide—Skin disorder—Docetaxel—pancreatic cancer	4.81e-05	0.000409	CcSEcCtD
Temozolomide—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	4.8e-05	0.000409	CcSEcCtD
Temozolomide—Diarrhoea—Gemcitabine—pancreatic cancer	4.77e-05	0.000406	CcSEcCtD
Temozolomide—Neuropathy peripheral—Doxorubicin—pancreatic cancer	4.75e-05	0.000404	CcSEcCtD
Temozolomide—Dizziness—Irinotecan—pancreatic cancer	4.73e-05	0.000403	CcSEcCtD
Temozolomide—Haemoglobin—Epirubicin—pancreatic cancer	4.72e-05	0.000402	CcSEcCtD
Temozolomide—Stomatitis—Doxorubicin—pancreatic cancer	4.72e-05	0.000402	CcSEcCtD
Temozolomide—Anorexia—Docetaxel—pancreatic cancer	4.72e-05	0.000402	CcSEcCtD
Temozolomide—Urinary tract infection—Doxorubicin—pancreatic cancer	4.71e-05	0.000401	CcSEcCtD
Temozolomide—Haemorrhage—Epirubicin—pancreatic cancer	4.7e-05	0.0004	CcSEcCtD
Temozolomide—Hepatitis—Epirubicin—pancreatic cancer	4.7e-05	0.0004	CcSEcCtD
Temozolomide—Diarrhoea—Fluorouracil—pancreatic cancer	4.69e-05	0.000399	CcSEcCtD
Temozolomide—Hypoaesthesia—Epirubicin—pancreatic cancer	4.67e-05	0.000398	CcSEcCtD
Temozolomide—Pharyngitis—Epirubicin—pancreatic cancer	4.66e-05	0.000397	CcSEcCtD
Temozolomide—Urinary tract disorder—Epirubicin—pancreatic cancer	4.64e-05	0.000395	CcSEcCtD
Temozolomide—Oedema peripheral—Epirubicin—pancreatic cancer	4.63e-05	0.000394	CcSEcCtD
Temozolomide—Connective tissue disorder—Epirubicin—pancreatic cancer	4.62e-05	0.000393	CcSEcCtD
Temozolomide—Urethral disorder—Epirubicin—pancreatic cancer	4.6e-05	0.000392	CcSEcCtD
Temozolomide—Hepatobiliary disease—Doxorubicin—pancreatic cancer	4.58e-05	0.00039	CcSEcCtD
Temozolomide—Vomiting—Irinotecan—pancreatic cancer	4.55e-05	0.000387	CcSEcCtD
Temozolomide—Sinusitis—Doxorubicin—pancreatic cancer	4.54e-05	0.000387	CcSEcCtD
Temozolomide—Dizziness—Fluorouracil—pancreatic cancer	4.53e-05	0.000386	CcSEcCtD
Temozolomide—Visual impairment—Epirubicin—pancreatic cancer	4.53e-05	0.000385	CcSEcCtD
Temozolomide—Rash—Irinotecan—pancreatic cancer	4.51e-05	0.000384	CcSEcCtD
Temozolomide—Dermatitis—Irinotecan—pancreatic cancer	4.51e-05	0.000384	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	4.51e-05	0.000384	CcSEcCtD
Temozolomide—Headache—Irinotecan—pancreatic cancer	4.48e-05	0.000382	CcSEcCtD
Temozolomide—Insomnia—Docetaxel—pancreatic cancer	4.47e-05	0.000381	CcSEcCtD
Temozolomide—Paraesthesia—Docetaxel—pancreatic cancer	4.44e-05	0.000378	CcSEcCtD
Temozolomide—Erythema multiforme—Epirubicin—pancreatic cancer	4.44e-05	0.000378	CcSEcCtD
Temozolomide—Vomiting—Gemcitabine—pancreatic cancer	4.43e-05	0.000377	CcSEcCtD
Temozolomide—Dyspnoea—Docetaxel—pancreatic cancer	4.41e-05	0.000376	CcSEcCtD
Temozolomide—Somnolence—Docetaxel—pancreatic cancer	4.4e-05	0.000374	CcSEcCtD
Temozolomide—Rash—Gemcitabine—pancreatic cancer	4.4e-05	0.000374	CcSEcCtD
Temozolomide—Dermatitis—Gemcitabine—pancreatic cancer	4.39e-05	0.000374	CcSEcCtD
Temozolomide—Eye disorder—Epirubicin—pancreatic cancer	4.39e-05	0.000374	CcSEcCtD
Temozolomide—Tinnitus—Epirubicin—pancreatic cancer	4.38e-05	0.000373	CcSEcCtD
Temozolomide—Haemoglobin—Doxorubicin—pancreatic cancer	4.37e-05	0.000372	CcSEcCtD
Temozolomide—Headache—Gemcitabine—pancreatic cancer	4.37e-05	0.000372	CcSEcCtD
Temozolomide—Flushing—Epirubicin—pancreatic cancer	4.36e-05	0.000371	CcSEcCtD
Temozolomide—Cardiac disorder—Epirubicin—pancreatic cancer	4.36e-05	0.000371	CcSEcCtD
Temozolomide—Vomiting—Fluorouracil—pancreatic cancer	4.36e-05	0.000371	CcSEcCtD
Temozolomide—Dyspepsia—Docetaxel—pancreatic cancer	4.35e-05	0.000371	CcSEcCtD
Temozolomide—Hepatitis—Doxorubicin—pancreatic cancer	4.35e-05	0.00037	CcSEcCtD
Temozolomide—Haemorrhage—Doxorubicin—pancreatic cancer	4.35e-05	0.00037	CcSEcCtD
Temozolomide—Hypoaesthesia—Doxorubicin—pancreatic cancer	4.32e-05	0.000368	CcSEcCtD
Temozolomide—Rash—Fluorouracil—pancreatic cancer	4.32e-05	0.000368	CcSEcCtD
Temozolomide—Dermatitis—Fluorouracil—pancreatic cancer	4.32e-05	0.000368	CcSEcCtD
Temozolomide—Pharyngitis—Doxorubicin—pancreatic cancer	4.31e-05	0.000367	CcSEcCtD
Temozolomide—Decreased appetite—Docetaxel—pancreatic cancer	4.3e-05	0.000366	CcSEcCtD
Temozolomide—Headache—Fluorouracil—pancreatic cancer	4.29e-05	0.000366	CcSEcCtD
Temozolomide—Urinary tract disorder—Doxorubicin—pancreatic cancer	4.29e-05	0.000365	CcSEcCtD
Temozolomide—Oedema peripheral—Doxorubicin—pancreatic cancer	4.28e-05	0.000365	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Docetaxel—pancreatic cancer	4.27e-05	0.000364	CcSEcCtD
Temozolomide—Connective tissue disorder—Doxorubicin—pancreatic cancer	4.27e-05	0.000364	CcSEcCtD
Temozolomide—Fatigue—Docetaxel—pancreatic cancer	4.27e-05	0.000363	CcSEcCtD
Temozolomide—Angiopathy—Epirubicin—pancreatic cancer	4.26e-05	0.000363	CcSEcCtD
Temozolomide—Urethral disorder—Doxorubicin—pancreatic cancer	4.26e-05	0.000363	CcSEcCtD
Temozolomide—Nausea—Irinotecan—pancreatic cancer	4.25e-05	0.000362	CcSEcCtD
Temozolomide—Immune system disorder—Epirubicin—pancreatic cancer	4.24e-05	0.000361	CcSEcCtD
Temozolomide—Mediastinal disorder—Epirubicin—pancreatic cancer	4.23e-05	0.00036	CcSEcCtD
Temozolomide—Constipation—Docetaxel—pancreatic cancer	4.23e-05	0.00036	CcSEcCtD
Temozolomide—Pain—Docetaxel—pancreatic cancer	4.23e-05	0.00036	CcSEcCtD
Temozolomide—Chills—Epirubicin—pancreatic cancer	4.21e-05	0.000359	CcSEcCtD
Temozolomide—Visual impairment—Doxorubicin—pancreatic cancer	4.19e-05	0.000357	CcSEcCtD
Temozolomide—Alopecia—Epirubicin—pancreatic cancer	4.15e-05	0.000353	CcSEcCtD
Temozolomide—Nausea—Gemcitabine—pancreatic cancer	4.14e-05	0.000353	CcSEcCtD
Temozolomide—Mental disorder—Epirubicin—pancreatic cancer	4.11e-05	0.00035	CcSEcCtD
Temozolomide—Erythema multiforme—Doxorubicin—pancreatic cancer	4.11e-05	0.00035	CcSEcCtD
Temozolomide—Erythema—Epirubicin—pancreatic cancer	4.09e-05	0.000348	CcSEcCtD
Temozolomide—Malnutrition—Epirubicin—pancreatic cancer	4.09e-05	0.000348	CcSEcCtD
Temozolomide—Feeling abnormal—Docetaxel—pancreatic cancer	4.08e-05	0.000347	CcSEcCtD
Temozolomide—Nausea—Fluorouracil—pancreatic cancer	4.07e-05	0.000347	CcSEcCtD
Temozolomide—Eye disorder—Doxorubicin—pancreatic cancer	4.06e-05	0.000346	CcSEcCtD
Temozolomide—Tinnitus—Doxorubicin—pancreatic cancer	4.05e-05	0.000345	CcSEcCtD
Temozolomide—Gastrointestinal pain—Docetaxel—pancreatic cancer	4.05e-05	0.000344	CcSEcCtD
Temozolomide—Flushing—Doxorubicin—pancreatic cancer	4.03e-05	0.000343	CcSEcCtD
Temozolomide—Cardiac disorder—Doxorubicin—pancreatic cancer	4.03e-05	0.000343	CcSEcCtD
Temozolomide—Dysgeusia—Epirubicin—pancreatic cancer	4e-05	0.000341	CcSEcCtD
Temozolomide—Back pain—Epirubicin—pancreatic cancer	3.95e-05	0.000337	CcSEcCtD
Temozolomide—Angiopathy—Doxorubicin—pancreatic cancer	3.94e-05	0.000336	CcSEcCtD
Temozolomide—Immune system disorder—Doxorubicin—pancreatic cancer	3.93e-05	0.000334	CcSEcCtD
Temozolomide—Mediastinal disorder—Doxorubicin—pancreatic cancer	3.92e-05	0.000333	CcSEcCtD
Temozolomide—Abdominal pain—Docetaxel—pancreatic cancer	3.91e-05	0.000333	CcSEcCtD
Temozolomide—Body temperature increased—Docetaxel—pancreatic cancer	3.91e-05	0.000333	CcSEcCtD
Temozolomide—Chills—Doxorubicin—pancreatic cancer	3.9e-05	0.000332	CcSEcCtD
Temozolomide—Vision blurred—Epirubicin—pancreatic cancer	3.85e-05	0.000328	CcSEcCtD
Temozolomide—Alopecia—Doxorubicin—pancreatic cancer	3.84e-05	0.000327	CcSEcCtD
Temozolomide—Mental disorder—Doxorubicin—pancreatic cancer	3.81e-05	0.000324	CcSEcCtD
Temozolomide—Ill-defined disorder—Epirubicin—pancreatic cancer	3.79e-05	0.000323	CcSEcCtD
Temozolomide—Malnutrition—Doxorubicin—pancreatic cancer	3.78e-05	0.000322	CcSEcCtD
Temozolomide—Erythema—Doxorubicin—pancreatic cancer	3.78e-05	0.000322	CcSEcCtD
Temozolomide—Anaemia—Epirubicin—pancreatic cancer	3.78e-05	0.000322	CcSEcCtD
Temozolomide—Agitation—Epirubicin—pancreatic cancer	3.76e-05	0.00032	CcSEcCtD
Temozolomide—Dysgeusia—Doxorubicin—pancreatic cancer	3.7e-05	0.000315	CcSEcCtD
Temozolomide—Malaise—Epirubicin—pancreatic cancer	3.69e-05	0.000314	CcSEcCtD
Temozolomide—Vertigo—Epirubicin—pancreatic cancer	3.67e-05	0.000313	CcSEcCtD
Temozolomide—Leukopenia—Epirubicin—pancreatic cancer	3.66e-05	0.000312	CcSEcCtD
Temozolomide—Back pain—Doxorubicin—pancreatic cancer	3.66e-05	0.000312	CcSEcCtD
Temozolomide—Hypersensitivity—Docetaxel—pancreatic cancer	3.64e-05	0.00031	CcSEcCtD
Temozolomide—Palpitations—Epirubicin—pancreatic cancer	3.61e-05	0.000308	CcSEcCtD
Temozolomide—Cough—Epirubicin—pancreatic cancer	3.57e-05	0.000304	CcSEcCtD
Temozolomide—Vision blurred—Doxorubicin—pancreatic cancer	3.57e-05	0.000304	CcSEcCtD
Temozolomide—Asthenia—Docetaxel—pancreatic cancer	3.55e-05	0.000302	CcSEcCtD
Temozolomide—Convulsion—Epirubicin—pancreatic cancer	3.54e-05	0.000302	CcSEcCtD
Temozolomide—Hypertension—Epirubicin—pancreatic cancer	3.53e-05	0.000301	CcSEcCtD
Temozolomide—Ill-defined disorder—Doxorubicin—pancreatic cancer	3.51e-05	0.000299	CcSEcCtD
Temozolomide—Pruritus—Docetaxel—pancreatic cancer	3.5e-05	0.000298	CcSEcCtD
Temozolomide—Anaemia—Doxorubicin—pancreatic cancer	3.5e-05	0.000298	CcSEcCtD
Temozolomide—Arthralgia—Epirubicin—pancreatic cancer	3.48e-05	0.000296	CcSEcCtD
Temozolomide—Myalgia—Epirubicin—pancreatic cancer	3.48e-05	0.000296	CcSEcCtD
Temozolomide—Agitation—Doxorubicin—pancreatic cancer	3.48e-05	0.000296	CcSEcCtD
Temozolomide—Anxiety—Epirubicin—pancreatic cancer	3.47e-05	0.000295	CcSEcCtD
Temozolomide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	3.46e-05	0.000294	CcSEcCtD
Temozolomide—Discomfort—Epirubicin—pancreatic cancer	3.44e-05	0.000293	CcSEcCtD
Temozolomide—Malaise—Doxorubicin—pancreatic cancer	3.41e-05	0.00029	CcSEcCtD
Temozolomide—Dry mouth—Epirubicin—pancreatic cancer	3.4e-05	0.00029	CcSEcCtD
Temozolomide—Vertigo—Doxorubicin—pancreatic cancer	3.4e-05	0.000289	CcSEcCtD
Temozolomide—Leukopenia—Doxorubicin—pancreatic cancer	3.39e-05	0.000288	CcSEcCtD
Temozolomide—Diarrhoea—Docetaxel—pancreatic cancer	3.38e-05	0.000288	CcSEcCtD
Temozolomide—Confusional state—Epirubicin—pancreatic cancer	3.36e-05	0.000286	CcSEcCtD
Temozolomide—Palpitations—Doxorubicin—pancreatic cancer	3.34e-05	0.000285	CcSEcCtD
Temozolomide—Anaphylactic shock—Epirubicin—pancreatic cancer	3.34e-05	0.000284	CcSEcCtD
Temozolomide—Oedema—Epirubicin—pancreatic cancer	3.34e-05	0.000284	CcSEcCtD
Temozolomide—Infection—Epirubicin—pancreatic cancer	3.32e-05	0.000282	CcSEcCtD
Temozolomide—Cough—Doxorubicin—pancreatic cancer	3.3e-05	0.000281	CcSEcCtD
Temozolomide—Convulsion—Doxorubicin—pancreatic cancer	3.28e-05	0.000279	CcSEcCtD
Temozolomide—Nervous system disorder—Epirubicin—pancreatic cancer	3.27e-05	0.000279	CcSEcCtD
Temozolomide—Dizziness—Docetaxel—pancreatic cancer	3.27e-05	0.000279	CcSEcCtD
Temozolomide—Thrombocytopenia—Epirubicin—pancreatic cancer	3.27e-05	0.000278	CcSEcCtD
Temozolomide—Hypertension—Doxorubicin—pancreatic cancer	3.27e-05	0.000278	CcSEcCtD
Temozolomide—Skin disorder—Epirubicin—pancreatic cancer	3.24e-05	0.000276	CcSEcCtD
Temozolomide—Hyperhidrosis—Epirubicin—pancreatic cancer	3.23e-05	0.000275	CcSEcCtD
Temozolomide—Arthralgia—Doxorubicin—pancreatic cancer	3.22e-05	0.000274	CcSEcCtD
Temozolomide—Myalgia—Doxorubicin—pancreatic cancer	3.22e-05	0.000274	CcSEcCtD
Temozolomide—Anxiety—Doxorubicin—pancreatic cancer	3.21e-05	0.000273	CcSEcCtD
Temozolomide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	3.2e-05	0.000272	CcSEcCtD
Temozolomide—Discomfort—Doxorubicin—pancreatic cancer	3.18e-05	0.000271	CcSEcCtD
Temozolomide—Anorexia—Epirubicin—pancreatic cancer	3.18e-05	0.000271	CcSEcCtD
Temozolomide—Dry mouth—Doxorubicin—pancreatic cancer	3.15e-05	0.000268	CcSEcCtD
Temozolomide—Vomiting—Docetaxel—pancreatic cancer	3.15e-05	0.000268	CcSEcCtD
Temozolomide—Rash—Docetaxel—pancreatic cancer	3.12e-05	0.000266	CcSEcCtD
Temozolomide—Dermatitis—Docetaxel—pancreatic cancer	3.12e-05	0.000265	CcSEcCtD
Temozolomide—Confusional state—Doxorubicin—pancreatic cancer	3.11e-05	0.000265	CcSEcCtD
Temozolomide—Headache—Docetaxel—pancreatic cancer	3.1e-05	0.000264	CcSEcCtD
Temozolomide—Anaphylactic shock—Doxorubicin—pancreatic cancer	3.09e-05	0.000263	CcSEcCtD
Temozolomide—Oedema—Doxorubicin—pancreatic cancer	3.09e-05	0.000263	CcSEcCtD
Temozolomide—Infection—Doxorubicin—pancreatic cancer	3.07e-05	0.000261	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	3.04e-05	0.000259	CcSEcCtD
Temozolomide—Nervous system disorder—Doxorubicin—pancreatic cancer	3.03e-05	0.000258	CcSEcCtD
Temozolomide—Thrombocytopenia—Doxorubicin—pancreatic cancer	3.02e-05	0.000257	CcSEcCtD
Temozolomide—Insomnia—Epirubicin—pancreatic cancer	3.02e-05	0.000257	CcSEcCtD
Temozolomide—Skin disorder—Doxorubicin—pancreatic cancer	3e-05	0.000255	CcSEcCtD
Temozolomide—Paraesthesia—Epirubicin—pancreatic cancer	3e-05	0.000255	CcSEcCtD
Temozolomide—Hyperhidrosis—Doxorubicin—pancreatic cancer	2.98e-05	0.000254	CcSEcCtD
Temozolomide—Dyspnoea—Epirubicin—pancreatic cancer	2.97e-05	0.000253	CcSEcCtD
Temozolomide—Somnolence—Epirubicin—pancreatic cancer	2.97e-05	0.000253	CcSEcCtD
Temozolomide—Anorexia—Doxorubicin—pancreatic cancer	2.94e-05	0.000251	CcSEcCtD
Temozolomide—Nausea—Docetaxel—pancreatic cancer	2.94e-05	0.00025	CcSEcCtD
Temozolomide—Dyspepsia—Epirubicin—pancreatic cancer	2.94e-05	0.00025	CcSEcCtD
Temozolomide—Decreased appetite—Epirubicin—pancreatic cancer	2.9e-05	0.000247	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Epirubicin—pancreatic cancer	2.88e-05	0.000245	CcSEcCtD
Temozolomide—Fatigue—Epirubicin—pancreatic cancer	2.88e-05	0.000245	CcSEcCtD
Temozolomide—Constipation—Epirubicin—pancreatic cancer	2.85e-05	0.000243	CcSEcCtD
Temozolomide—Pain—Epirubicin—pancreatic cancer	2.85e-05	0.000243	CcSEcCtD
Temozolomide—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	2.81e-05	0.00024	CcSEcCtD
Temozolomide—Insomnia—Doxorubicin—pancreatic cancer	2.79e-05	0.000238	CcSEcCtD
Temozolomide—Paraesthesia—Doxorubicin—pancreatic cancer	2.77e-05	0.000236	CcSEcCtD
Temozolomide—Dyspnoea—Doxorubicin—pancreatic cancer	2.75e-05	0.000234	CcSEcCtD
Temozolomide—Feeling abnormal—Epirubicin—pancreatic cancer	2.75e-05	0.000234	CcSEcCtD
Temozolomide—Somnolence—Doxorubicin—pancreatic cancer	2.74e-05	0.000234	CcSEcCtD
Temozolomide—Gastrointestinal pain—Epirubicin—pancreatic cancer	2.73e-05	0.000232	CcSEcCtD
Temozolomide—Dyspepsia—Doxorubicin—pancreatic cancer	2.72e-05	0.000231	CcSEcCtD
Temozolomide—Decreased appetite—Doxorubicin—pancreatic cancer	2.68e-05	0.000229	CcSEcCtD
Temozolomide—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	2.67e-05	0.000227	CcSEcCtD
Temozolomide—Fatigue—Doxorubicin—pancreatic cancer	2.66e-05	0.000227	CcSEcCtD
Temozolomide—Urticaria—Epirubicin—pancreatic cancer	2.65e-05	0.000226	CcSEcCtD
Temozolomide—Pain—Doxorubicin—pancreatic cancer	2.64e-05	0.000225	CcSEcCtD
Temozolomide—Constipation—Doxorubicin—pancreatic cancer	2.64e-05	0.000225	CcSEcCtD
Temozolomide—Abdominal pain—Epirubicin—pancreatic cancer	2.64e-05	0.000225	CcSEcCtD
Temozolomide—Body temperature increased—Epirubicin—pancreatic cancer	2.64e-05	0.000225	CcSEcCtD
Temozolomide—Feeling abnormal—Doxorubicin—pancreatic cancer	2.54e-05	0.000217	CcSEcCtD
Temozolomide—Gastrointestinal pain—Doxorubicin—pancreatic cancer	2.52e-05	0.000215	CcSEcCtD
Temozolomide—Hypersensitivity—Epirubicin—pancreatic cancer	2.46e-05	0.000209	CcSEcCtD
Temozolomide—Urticaria—Doxorubicin—pancreatic cancer	2.45e-05	0.000209	CcSEcCtD
Temozolomide—Body temperature increased—Doxorubicin—pancreatic cancer	2.44e-05	0.000208	CcSEcCtD
Temozolomide—Abdominal pain—Doxorubicin—pancreatic cancer	2.44e-05	0.000208	CcSEcCtD
Temozolomide—Asthenia—Epirubicin—pancreatic cancer	2.39e-05	0.000204	CcSEcCtD
Temozolomide—Pruritus—Epirubicin—pancreatic cancer	2.36e-05	0.000201	CcSEcCtD
Temozolomide—Diarrhoea—Epirubicin—pancreatic cancer	2.28e-05	0.000194	CcSEcCtD
Temozolomide—Hypersensitivity—Doxorubicin—pancreatic cancer	2.27e-05	0.000194	CcSEcCtD
Temozolomide—Asthenia—Doxorubicin—pancreatic cancer	2.22e-05	0.000189	CcSEcCtD
Temozolomide—Dizziness—Epirubicin—pancreatic cancer	2.21e-05	0.000188	CcSEcCtD
Temozolomide—Pruritus—Doxorubicin—pancreatic cancer	2.18e-05	0.000186	CcSEcCtD
Temozolomide—Vomiting—Epirubicin—pancreatic cancer	2.12e-05	0.000181	CcSEcCtD
Temozolomide—Diarrhoea—Doxorubicin—pancreatic cancer	2.11e-05	0.00018	CcSEcCtD
Temozolomide—Rash—Epirubicin—pancreatic cancer	2.1e-05	0.000179	CcSEcCtD
Temozolomide—Dermatitis—Epirubicin—pancreatic cancer	2.1e-05	0.000179	CcSEcCtD
Temozolomide—Headache—Epirubicin—pancreatic cancer	2.09e-05	0.000178	CcSEcCtD
Temozolomide—Dizziness—Doxorubicin—pancreatic cancer	2.04e-05	0.000174	CcSEcCtD
Temozolomide—Nausea—Epirubicin—pancreatic cancer	1.98e-05	0.000169	CcSEcCtD
Temozolomide—Vomiting—Doxorubicin—pancreatic cancer	1.96e-05	0.000167	CcSEcCtD
Temozolomide—Rash—Doxorubicin—pancreatic cancer	1.95e-05	0.000166	CcSEcCtD
Temozolomide—Dermatitis—Doxorubicin—pancreatic cancer	1.94e-05	0.000166	CcSEcCtD
Temozolomide—Headache—Doxorubicin—pancreatic cancer	1.93e-05	0.000165	CcSEcCtD
Temozolomide—Nausea—Doxorubicin—pancreatic cancer	1.83e-05	0.000156	CcSEcCtD
